Technetium-99m-HMPAO in Tourette's syndrome on neuroleptic therapy and after withdrawal

被引:0
|
作者
Lampreave, JL
Molina, V
Mardomingo, MJ
Bittini, A
Domínguez, P
Almoguera, I
Rubia, FJ
Carreras, JL
机构
[1] Hosp Gen Gregorio Maranon, Dept Nucl Med, E-28009 Madrid, Spain
[2] Hosp Gen Gregorio Maranon, Dept Psychiat, E-28009 Madrid, Spain
[3] Hosp Gen Gregorio Maranon, Infantile Psychiat Dept, E-28009 Madrid, Spain
[4] Univ Complutense Madrid, Brain Mapping Unit, Madrid, Spain
[5] Univ Complutense Madrid, Dept Radiol, Madrid, Spain
[6] Univ Complutense Madrid, PET Ctr, Madrid, Spain
关键词
Tourette's syndrome; brain perfusion; neuroleptic treatment; technetium-99m-HMPAO;
D O I
暂无
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Both decreased and increased perfusion and metabolism have been described with PET and SPECT in different areas of the brain in patients with Gilles de la Tourette's syndrome, The aim of this study was to define the regional cerebral perfusion pattern in drug-free patients and the changes in perfusion with the usual neuroleptic treatment, Methods: A group of 13 normal control subjects and 15 unmedicated Gilles de la Tourette's syndrome patients were studied with Tc-99m-HMPAO brain SPECT. Thirteen of the initial group of patients were retested on neuroleptic treatment. A semiquantitative analysis of the images was performed. Results: Decreased perfusion in orbital and anterior medial regions of both frontal lobes as well as in both temporal lobes was observed in the nontreated group compared with control subjects, With treatment, a perfusion increase in these frontal regions and in the left medial temporal cortex was observed. Conclusion: Neuroleptic treatment could decrease the hyperactivity of the dopaminergic system leading to improvement of the clinical symptoms and reperfusion of some previously hypoperfused regions.
引用
收藏
页码:624 / 628
页数:5
相关论文
共 50 条
  • [1] Asymmetry of basal ganglia perfusion in Tourette's syndrome shown by technetium-99m-HMPAO SPECT
    Klieger, PS
    Fett, KA
    Dimitsopulos, T
    Kurlan, R
    JOURNAL OF NUCLEAR MEDICINE, 1997, 38 (02) : 188 - 191
  • [2] PREPARATION OF TECHNETIUM-99M-HMPAO
    BALLINGER, J
    JOURNAL OF NUCLEAR MEDICINE, 1990, 31 (11) : 1892 - 1892
  • [3] Technetium-99m-HMPAO brain SPECT in Sjogren's syndrome
    Kao, CH
    Lan, JL
    ChangLai, SP
    Chieng, PU
    JOURNAL OF NUCLEAR MEDICINE, 1998, 39 (05) : 773 - 777
  • [4] Technetium-99m-HMPAO SPECT in Sturge-Weber syndrome
    BarSever, Z
    Connolly, LP
    Barnes, PD
    Treves, ST
    JOURNAL OF NUCLEAR MEDICINE, 1996, 37 (01) : 81 - 83
  • [5] Technetium-99m-HMPAO brain SPECT in patients with syndrome X
    Weidmann, B
    Jansen, WC
    Bock, A
    Assheuer, J
    Tauchert, MO
    AMERICAN JOURNAL OF CARDIOLOGY, 1997, 79 (07): : 959 - &
  • [6] Technetium-99m-HMPAO brain SPECT in Behcet's disease
    Garcia-Burillo, A
    Castell, J
    Fraile, M
    Jacas, C
    Vilardell, M
    Ortega, D
    Bosch, JA
    JOURNAL OF NUCLEAR MEDICINE, 1998, 39 (06) : 950 - 954
  • [7] TECHNETIUM-99M-HMPAO SPECT IN PARTIAL STATUS EPILEPTICUS
    TATUM, WO
    ALAVI, A
    STECKER, MM
    JOURNAL OF NUCLEAR MEDICINE, 1994, 35 (07) : 1087 - 1094
  • [8] Technetium-99m-HMPAO brain SPECT in anorexia nervosa
    Kuruoglu, AC
    Kapucu, Ö
    Atasever, T
    Arikan, Z
    Isik, E
    Ünlü, M
    JOURNAL OF NUCLEAR MEDICINE, 1998, 39 (02) : 304 - 306
  • [9] Cerebral perfusion in early and late opiate withdrawal: A technetium-99m-HMPAO SPECT study
    Rose, JS
    Branchey, M
    BuydensBranchey, L
    Stapleton, JM
    Chasten, K
    Werrell, A
    Maayan, ML
    PSYCHIATRY RESEARCH-NEUROIMAGING, 1996, 67 (01) : 39 - 47
  • [10] Cerebral sparganosis: Increased uptake of technetium-99m-HMPAO
    You, DL
    Tzen, KY
    Kao, PF
    Ho, YS
    Chu, CC
    JOURNAL OF NUCLEAR MEDICINE, 1997, 38 (06) : 939 - 941